Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Holland & Knight partner Rodney Bell in Miami assisted New Jersey-based Kos Pharmaceuticals in its $104 million acquisition of three existing cardiovascular drugs and three products in the development stage from Biovail Corp. In a deal announced May 3, Kos acquired Biovail’s anti-hypertension products Teveten and Teveten HCT and the sales and marketing rights for Cardizem LA. Kos also bought the marketing rights to three Biovail products that are in the development stage. Kos plans to hire 200 Biovail employees, including 150 salespeople, as it tries to expand its pharmaceutical focus on cardiovascular and cholesterol issues. Kos expects the products to boost revenue by 8 percent in 2005 to about $720 million, according to a company release. “It expands their cardiovascular capabilities and diversifies their products,” Bell said. Bell and his team of a half-dozen attorneys worked several “all-nighters” to get the deal done as quick as possible, which turned out to be only a “few weeks.” The deal was complicated by regulatory issues with the Food and Drug Administration, which oversees development and sales of pharmaceuticals. “There are some regulatory issues that go into it,” Bell said. “It is not like bringing a new product to the market for the first time.” Bell leads the law firm’s South Florida securities and public companies practice. The 15-person practice focuses on capital markets, corporate governance and mergers and acquisitions.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.